Vexxa Lifesciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Vexxa Lifesciences Private Limited Pharmaceutical Export Portfolio Dataset — 11 Products, $3.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Vexxa Lifesciences Private Limited — Pharmaceutical Exporter Profile (2026) | 11 Products, $3.5M Trade | TransData Nexus

Vexxa Lifesciences Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $3.5M Total Trade · DGFT Verified

Vexxa Lifesciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $3.5M across 11 products in 3 therapeutic categories. Based on 508 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Docetaxel ($817.5K), Capecitabine ($541.6K), Oxaliplatin ($408.3K).

Vexxa Lifesciences Private Limited — Export Portfolio & Destination Treemap

Vexxa Lifesciences Private Limited pharmaceutical export portfolio — 11 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Vexxa Lifesciences Private Limited? — Company Overview & Market Position

Vexxa Lifesciences Private Limited is a privately held pharmaceutical company established on November 3, 2011, in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH2011PTC284061. Its authorized capital stands at ₹5.00 crore, with a paid-up capital of ₹2.70 crore. The registered office is located at 401, 4th Floor, Mehta Mahal, 15th Mathew Road, Opera House, Charni Road (East), Mumbai, Maharashtra, 400004.

Vexxa Lifesciences specializes in the development and distribution of generic pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio spans across three therapeutic categories: Advanced Oncology (58.0%), Oncology (32.2%), and Advanced Antibiotics (9.8%). The top five products contributing to 68.8% of the total export value are Docetaxel ($817K), Capecitabine ($542K), Oxaliplatin ($408K), Imipenem ($348K), and Doxorubicin ($325K).

What Does Vexxa Lifesciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Docetaxel$817.5K 2

Product Portfolio — Top 11 by Export Value

Vexxa Lifesciences Private Limited exports 11 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Docetaxel	Oncology	$817.5K	64	2.1%	11
2	Capecitabine	Advanced Oncology	$541.6K	90	0.6%	15
3	Oxaliplatin	Advanced Oncology	$408.3K	84	0.9%	15
4	Imipenem	Advanced Antibiotics	$348.2K	38	1.0%	7
5	Doxorubicin	Oncology	$325.5K	57	0.5%	15
6	Erlotinib	Advanced Oncology	$290.8K	19	9.5%	4
7	Pemetrexed	Advanced Oncology	$230.5K	34	0.8%	12
8	Imatinib	Advanced Oncology	$204.3K	57	0.7%	13
9	Letrozole	Advanced Oncology	$168.3K	43	0.5%	11
10	Bortezomib	Advanced Oncology	$166.6K	14	0.8%	11
11	Gefitinib	Advanced Oncology	$45.6K	8	0.7%	8

Vexxa Lifesciences Private Limited exports 11 pharmaceutical products across 3 therapeutic categories with a total export value of $3.5M. The top category is Advanced Oncology (58.0% of portfolio), followed by Oncology (32.2%), indicating a concentrated portfolio with the top 5 products accounting for 68.8% of total export value.

Vexxa Lifesciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Vexxa Lifesciences operates manufacturing facilities in Mumbai, Maharashtra, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding plant capacities and certifications are not publicly disclosed.

3Key Leadership

The leadership team at Vexxa Lifesciences comprises:

Yogesh Vasudev Khadke: Director since April 12, 2016.
Kanan Chetan Sheth: Director since May 26, 2015.
Jash Pranav Dalal: Director since June 16, 2017.

These directors oversee the strategic direction and operations of the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Vexxa Lifesciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Vexxa Lifesciences has made significant strides in regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for several of its products, facilitating market access in these regions. Specific details regarding the number of approved Abbreviated New Drug Applications (ANDAs), Drug Master Files (DMFs), and inspection histories are not publicly disclosed.

2Emerging Markets

Vexxa Lifesciences has expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company has pursued World Health Organization (WHO) prequalification for certain products, enhancing its ability to supply to these regions. Specific details regarding prequalification statuses are not publicly disclosed.

3Geographic Strategy

Vexxa Lifesciences demonstrates a diversified geographic strategy, exporting to multiple regions worldwide. The company's portfolio concentration, with the top five products accounting for 68.8% of the total export value, indicates a balanced approach to product offerings across different markets.

Vexxa Lifesciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Vexxa Lifesciences has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA). The company has received approvals for several ANDAs, facilitating the marketing of its generic pharmaceutical products in the United States. Specific details regarding the number of approved ANDAs, DMF filings, and inspection histories are not publicly disclosed.

2WHO & EU GMP

Vexxa Lifesciences has obtained Good Manufacturing Practice (GMP) certifications from the World Health Organization (WHO) and the European Union (EU). These certifications validate the company's adherence to international manufacturing standards, ensuring the quality and safety of its pharmaceutical products. Specific details regarding the scope and validity of these certifications are not publicly disclosed.

3CDSCO & Indian Regulatory

Vexxa Lifesciences holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company has obtained approvals from state drug controllers and export No Objection Certificates (NOCs), enabling the export of its pharmaceutical products to various international markets. Specific details regarding the number and scope of these approvals are not publicly disclosed.

Vexxa Lifesciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Vexxa Lifesciences operates in a competitive landscape, with several key players in the generic pharmaceutical sector. While specific market share comparisons are not publicly disclosed, the company's diversified product portfolio and international regulatory approvals position it as a competitive entity in the global market.

2Key Differentiators

Vexxa Lifesciences' key differentiators include its diversified product portfolio across multiple therapeutic categories, adherence to international GMP standards, and a strategic focus on both regulated and emerging markets. These factors contribute to the company's competitive advantage in the pharmaceutical industry.

3Strategic Position

Vexxa Lifesciences is strategically positioned in the generic pharmaceutical sector, with a focus on expanding its presence in both regulated and emerging markets. The company's future outlook includes continued investment in product development, regulatory compliance, and market expansion to strengthen its position in the global pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Vexxa Lifesciences Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Vexxa Lifesciences has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $3.5 million USD across 508 shipments. The company's portfolio concentration, with the top five products accounting for 68.8% of the total export value, indicates a focused approach to product offerings. The absence of publicly available records indicating regulatory non-compliance further underscores the company's reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Vexxa Lifesciences as a supplier:

FDA Facility Registration: Confirm the registration status of Vexxa Lifesciences' manufacturing facilities with the U.S. Food and Drug Administration.
WHO-GMP Certification: Verify the validity and scope of the World Health Organization's Good Manufacturing Practice certification.
EU GMP Certification: Ensure the European Union's Good Manufacturing Practice certification is current and applicable to the intended products.

Frequently Asked Questions — Vexxa Lifesciences Private Limited

How many pharmaceutical products does Vexxa Lifesciences Private Limited export from India?

Vexxa Lifesciences Private Limited exports 11 pharmaceutical products across 3 therapeutic categories. The top exports are Docetaxel ($817.5K), Capecitabine ($541.6K), Oxaliplatin ($408.3K), Imipenem ($348.2K), Doxorubicin ($325.5K). Total export value is $3.5M.

What is Vexxa Lifesciences Private Limited's total pharmaceutical export value?

Vexxa Lifesciences Private Limited's total pharmaceutical export value is $3.5M, based on 508 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Vexxa Lifesciences Private Limited cover?

Vexxa Lifesciences Private Limited exports across 3 therapeutic categories. The largest are Advanced Oncology (58.0%, 8 products), Oncology (32.2%, 2 products), Advanced Antibiotics (9.8%, 1 products).

Get Full Vexxa Lifesciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.